Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial
BMC Cancer, pp. 1-10, 2020.
Locally advanced Non-small-cell lung cancer ECOG 2 Chemoradiotherapy EfficacyMore(1+)
There is no consensus on the therapeutic approach to ECOG 2 patients with locally advanced non-small-cell lung cancer (LA-NSCLC), despite the sizable percentage of these patients in clinical practice. This study focused on the efficacy, toxicity and the optimal chemotherapy regimen of CCRT in ECOG 2 patients in a phase III trial. Patients...More
Full Text (Upload PDF)
PPT (Upload PPT)